Search results
Your search for Orgran returned no results
Showing 271 to 285 of 319 results for organ
Showing 271 to 285 of 319 results for organ
Evidence-based recommendations on minimally invasive oesophagectomy. This involves making small cuts or holes in the chest wall and inserting a camera and other instruments into the chest cavity to carry out the operation.
View recommendations for IPG407Show all sections
Sections for IPG407
Evidence-based recommendations on PneuX to prevent ventilator-associated pneumonia.
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Biographies for all current members of the diagnostics advisory committee.
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (HTG607)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
NICE has developed a medtech innovation briefing (MIB) on Butterfly iQ+ for diagnostic ultrasound imaging .
Evidence-based recommendations on relugolix–estradiol–norethisterone acetate (Ryeqo) for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
Intrabeam radiotherapy system for adjuvant treatment of early breast cancer (TA501)
Evidence-based recommendations on using Intrabeam radiotherapy during breast-conserving surgery in adults.
Evidence-based recommendations on tucatinib (TUKYSA) for HER2-positive locally advanced or metastatic breast cancer in adults after 2 or more anti-HER2 treatment therapies.
NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .
This guideline covers identifying and managing menopause, including in people with premature ovarian insufficiency. It aims to improve the consistency of support and information provided to people experiencing menopause.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.